Canada markets closed

Aequus Pharmaceuticals Inc. (AQS.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.0450-0.0050 (-10.00%)
At close: 03:43PM EDT

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • G
    Greg
    current market cap around 10million, SCOPE should bring in around 10million per year, imed bringing in around 20 mill per year in Canada and they are very comparable companies. Once they get their products rolling, aqs going to be making big money. They just need to survive a couple more quarters then will start seeing positive cash flow
  • O
    Oscar
    Seems like there’s a price disconnect between the Canadian side and the US side. Canadian side .075 Canadian. Or have they just not updated yet?
  • O
    Oscar
    I suppose traders don’t know which way the stock price will break. No one seems to be trading. The last news was pretty good but revenue generation may take awhile. Is it worth the wait???
  • M
    MFO
    New products means new revenues , so it s certainly good news. What revenues will they generate from this deal would surely be interesting to know ?
  • O
    Oscar
    Anyone planning in attending the quarterly meeting?
  • O
    Oscar
    Ok that was pretty good news in yesterday’s PR. Let’s see if Mr. Jansen can turn this into a cash machine. “Show me the Money”.
  • O
    Oscar
    Ok who bought 100 shares? Are you trying to make us feel good? It’s going to take a lot more than that to make longs happy.
  • d
    djchill
    More dry eye products!? good luck cuz that's all got.
  • a
    andre
    I would like to summarize and furthermore add some more information to the news of last week.

    This is by now the news with the biggest impact on the business of AQS.

    British Columbia decided to replace the existing product with Sandoz Tacrolismus. We talk about approx. 5.000 patients and additional 300 to 400 new patients every year, needing Sandoz Tacrolismus on a daily basis. We talk about a business worth up to 20 Mio CADs for the current product.

    And the best is: The impact on the revenue startet already end of last year and will rapidly grow this quarter, as all patients should have Sandoz Tacrolismus end of March latest.

    AQS will not generate 20 Mio CADs per year, as:

    - they will not get the whole revenue, Sandoz will have of course a part of it.
    - Sandoz is cheaper than the current product
    - Tacro IR patients will not (yet) be provided with Sandoz Tacro

    Anyway: Due to this deal, AQS will generate several millions CAD revenue year over year, without having additional sales cost.

    Therefore, we could be near to break even in a few quarters.

    And we have to see, if there is a need at all to raise new money, as revenue will grow rapidly from January on.

    This is the current situation without! the Evolve opportunity in Canada and later in in the US.

    It will be interesting to see, when the market starts to understand the complete new situation of AQS.
  • O
    Oscar
    Been in for a while. When I first starting buying shares in the Company. It was going to have five to ten patches or drug’s out. The CEO estimated, once they got going, each one was 5-30 million in sales per year. Jansen, also stated that big pharma’s coffee bill per year was more than they would make per year. AQSZF just needed to find a niche. My estimate is that they are three years behind schedule. You can eliminate one for the plandemic. So, now the question comes down to revenue. Last quarter results should come out positive. How much is needed to get this smoldering company to set on fire? Definitely, double digit numbers will help. We will soon find out if the longs made the right choice. Good luck!
  • M
    MFO
    Good news : 😊 the current commercial relationship between Aequus and Sandoz regarding Glaucoma medication Vistitan™ will remain in place until February 2022. The two parties continue to discuss extending and expanding the relationship to potentially include additional products beyond Vistitan™ and Tacrolimus.
  • M
    MFO
    For the year ended December 31, 2020, the Vancouver, British Columbia-based specialty pharmaceutical company reported its highest annual revenue to date of $2.6 million, up 59%, compared to $1.6 million during the year ended December 31, 2019. The company chalked the bump in revenue to higher sales. 
    For the fourth quarter ended December 31, 2020, the company clocked up $851,187 in revenue, a 59% increase, compared to the same quarter a year earlier.
  • M
    MFO
    Waiting for this approval … products are fine and now the management team seems ready for growth
  • M
    MFO
    Record Third Quarter Revenues – 67% Increase Over Same Period Last Year

    Even if the 3rd Evolve product will be sold OTC (or not), the future is bright as there will be new developments and products for this company .
  • J
    JPV
    New record revenue of 579.5k CAD in Q1/2020 with a strong +76% compared to Q1/2019. Operational breakeven anticipated for Q4/2020, profitability for 2021.
    New record revenue of 579.5k CAD in Q1/2020 with a strong +76% compared to Q1/2019. Operational breakeven anticipated for Q4/2020, profitability for 2021.
    seekingalpha.com
  • Y
    Yves
    I think there is a good probability that the company has reached profitability by now and is already in good shape...
    How else could we explain they could operate till now without more financing...
    They have certainly increased their sale of Tacrolimus for the reasons that everybody knows...
    On top of that, they reduced expenses...
    We just have to wait for another 6 months to see more improvements but nobody will go out of business in the meantime...
  • A
    A
    For the last 2 or so years, there has been an incongruence between the optimism on this message board and the share price. I still passively follow this company, although I am presently not invested in it. I wonder if now is a good time to buy cheap shares, or if this one is a trap. Perhaps short term trades when the shares dip below 17 cents (Canadian) are the way to play this one. What do the optimists have to say about things now that the price per share is lower than where it was over one year ago?
  • T
    Tim
    Nobody noticed the Q3 figures yet?
    https://money.tmx.com/en/quote/AQS/news/5304548027597480/Aequus_Reports_Third_Quarter_2021_Financial_Highlights

    712k C$ of revenue and 381k C$ as a quarterly loss. Revenue increasing constantly, very nice. Evolve sales increased from 18k (Q2) to 43k (Q3) so it's getting some traction now.
    TMX Money
    money.tmx.com
  • D
    Daniel
    Tacrolimus agaist Covid-19 / Coronavirus!

    https://www.sciencedaily.com/releases/2020/03/200330152143.h… A recent study has found that there is no evidence for or against the use of non-steroidal anti-inflammatory drugs such as ibuprofen for patients with COVID-19. The study, led by researchers at King's College London, also found other types of drugs, such as TNF blockers and JAK inhibitors safe to use. 89 existing studies on other coronavirus strains such as MERS and SARS, as well as the limited literature on COVID-19, were analysed to find out if certain pain medications, steroids, and other drugs used in people already suffering from diseases should be avoided if they catch COVID-19. Some patients, for example those with cancer, are already given immunosuppressive drugs -- therapies that can lower the body's immune system -- or immunostimulant drugs -- therapies that boost it. If these patients then catch COVID-19, doctors need to know what medication to stop. Dr Mieke Van Hemelrijck, a cancer epidemiologist and an author on the paper, said "This pandemic has led to challenging decision-making about the treatment of COVID-19 patients who were already critically unwell. In parallel, doctors across multiple specialties are making clinical decisions about the appropriate continuation of treatments for patients with chronic illnesses requiring immune suppressive medication." The article has been published in ecancermedicalscience, an open access oncology journal, and is authored by researchers from King's College London and Guy's and St. Thomas NHS Foundation Trust, London. There had been some speculation that non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen might make things worse for some COVID-19 patients, but the researchers did not find evidence to support this statement. Other types of drugs such as TNF blockers and JAK inhibitors, used to treat arthritis or other forms of inflammation, were also found to be safe to use. Another class of drug known as anti-interleukin-6 agents is being investigated for helping to fight COVID-19, although there is no conclusive proof yet. The researchers found that low amounts of prednisolone or tacrolimus therapy may be helpful in treating COVID-19. Co- author, Dr Sophie Papa, a medical oncologist and immunologist said: "Current evidence suggests that low dose prednisolone (a steroid used to treat allergies) and tacrolimus therapy (an immunosuppressive drug given to patients who have had an organ transplant) may have beneficial impact on the course of coronavirus infections. However further investigation is needed." As more people catch the disease, researchers will continue to investigate how it interacts with commonly used medications and make further guidance recommendations.